Important Aspects of Post-Prandial Antidiabetic Drug, Acarbose

Author(s): Rajeev Kumar Singla , Radha Singh , Ashok Kumar Dubey .

Journal Name: Current Topics in Medicinal Chemistry

Volume 16 , Issue 23 , 2016

Become EABM
Become Reviewer

Abstract:

Acarbose, a well known and efficacious α-amylase and α-glucosidase inhibitor, is a postprandial acting antidiabetic drug. DNS-based α-amylase inhibitory assays showed that use of acarbose at concentrations above 125 µg/ml resulted in release of reducing sugar in the reaction, an unexpected observation. Objective of the present study was to design experimental strategies to address this unusual finding. Acarbose was found to be susceptible to thermo-lysis. Further, besides being an inhibitor, it could also be hydrolyzed by porcine pancreatic α-amylase, but had weaker affinity for α - amylase compared to starch. GRIP docking was done for the mechanistic analysis of the active site in the enzyme for substrate, inhibitor and, inhibitor’s metabolite (K2). Interaction between acarbose and α-amylase involved significant hydrogen binding compared to that of starch, producing a stronger enzyme-inhibitor complex. Further, docking analysis led us to predict the site on α-amylase where the inhibitor (acarbose) bound more tightly, which possibly affected the binding and hydrolysis of starch exerting its effective anti-diabetic function.

Keywords: α-Amylase inhibitor; GRIP docking; Antidiabetic agents; Acarbose; Pseudotetrasaccharide.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 23
Year: 2016
Page: [2625 - 2633]
Pages: 9
DOI: 10.2174/1568026616666160414123500
Price: $58

Article Metrics

PDF: 43
HTML: 6
EPUB: 1
PRC: 1